Greater

health

Telix Pharmaceuticals and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market

MELBOURNE, Australia and HONG KONG, Nov. 02, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into a strategic licence and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited (‘China Grand Pharma’) for Telix’s portfolio of Molecularly-Targeted Radiation (‘MTR’) products.

Telix has appointed China Grand Pharma as its exclusive partner for the Greater China market (‘Territory’)1 and grants China Grand Pharma exclusive development and commercialisation rights to Telix’s portfolio of prostate, renal and brain (glioblastoma) cancer imaging and therapeutic MTR products in the Territory.

Leveraging off China Grand Pharma’s capabilities and infrastructure in China, Telix will enter a significant oncology market, and by partnering with Telix, China Grand Pharma will build on its pipeline of innovative products for Greater China, as well as its strategy in Nuclear Medicine.   

The material terms of the partnership include:

Therapeutic Products

  • US$25M (~AU$35M) up-front non-refundable prepayment to Telix, to be credited against future regulatory and commercial milestone payments.

  • Up to US$225M (~AU$315M) in regulatory and commercial milestone payments to Telix, across Telix’s existing therapeutic products portfolio.

  • Program-related investment estimated at up to US$65M (~AU$90M) for clinical costs associated with the development of the therapeutic products in the Territory, to align with Telix’s global clinical development programs.

  • Royalties on therapeutic product sales in the Territory, in addition to milestone payments.

Imaging Products

  • Exclusive commercial partnership (sales, marketing, distribution) for Telix’s core imaging product portfolio:

    • TLX250-CDx (89Zr-Girentuximab) for renal cancer, and;

    • TLX591-CDx (68Ga-PSMA), TLX599-CDx (99Tc-PSMA) for prostate cancer.

Strategic Equity Investment

Additionally, China Grand Pharma will make a simultaneous one-time strategic equity investment of US$25M (~AU$35M) in Telix. The investment is in the form of a private placement to China Grand Pharma of 20,947,181 fully paid ordinary Telix shares representing a post-issue holding by China Grand Pharma of 7.62%. Shares will be issued at a price of AU$1.69, based on the 10-day volume-weighted average price (‘VWAP’) for Telix shares up to and including 28th October 2020. Shares will be issued no later than November 06 2020, following receipt of the placement proceeds. Shares issued to China Grand Pharma are subject to a holding lock and will not be able to be traded for a period of 12 months from the date of issue. In addition, China Grand Pharma is subject to a standstill provision and is unable to trade in Telix shares for a period of 12 months.

Telix Pharmaceuticals CEO, Dr. Chris Behrenbruch stated, “Telix’s mission is to be a leading global oncology company and China is an important future market for our products. We are pleased to be working with China Grand Pharma to deliver our diagnostic imaging and therapeutic products to cancer patients in China. Considering the successful acquisition of Sirtex Medical Limited with joint venture private equity partner CDH Genetech Limited2 and subsequent approval of a New Drug Application filing for SIR-Spheres® by the National Medical Products Administration (‘NMPA’) of the

Read More
health

Grocery workers at greater risk for COVID without symptoms

Grocery workers are likely at greater risk of infection with the new coronavirus, a new study shows.

Not only that, but because a high percentage of them have no symptoms when they are infected, they could become sources of future spread, the researchers said.

For the study, Harvard University T.H. Chan School of Public Health scientists studied the test results of workers at a single grocery store in Boston. One in five workers (20%) tested positive for SARS-CoV-2, and three-quarters of those with the virus had no symptoms.

These essential workers could be an important reservoir of infection, the investigators said. “Once essential workers are infected with SARS-CoV-2, they may become a significant transmission source for the community they serve,” the researchers explained.

The percentage of those infected was much higher than the virus’s prevalence in the local community, which was 0.9% to 1.3% at that time. The grocery workers who had customer-facing jobs were five times more likely to test positive, the findings showed.

The study was published this week in the journal Occupational and Environmental Medicine. The grocery workers had the coronavirus tests in May as part of a mandatory testing policy in Boston.

The workers also answered questions about symptoms and exposures, and completed detailed questionnaires about their lifestyles, medical and employment histories, working patterns, role at the store, commuting to and from work, and the protective measures they were able to take against infection at work. Most also answered questionnaires focusing on anxiety and depression.

The study was small and specific to the one location, the researchers cautioned.

“This is the first study to demonstrate the significant asymptomatic infection rate, exposure risks, and associated psychological distress of grocery retail essential workers during the pandemic,” Justin Yang and colleagues said in a journal news release.

About one in four of the 99 employees who completed the mental health questions reported feeling at least mild anxiety. About half of those respondents weren’t able to consistently practice social distancing at work. Those who were able to practice social distancing tended to be less anxious, according to the report.

Eight of the employees were mildly depressed. They were less likely to practice social distancing at work and relied on shared rides or public transportation. Those who drove their own car, walked or biked were far less likely to report depression.

“Our significant mental health finding calls for action in providing comprehensive employee assistance services to help essential workers cope with the psychological distress during the COVID-19 pandemic,” the study authors said.

The researchers also recommended that employers and government officials implement routine COVID-19 employee testing, and strategies to reduce contact.

More information

The U.S. Centers for Disease Control and Prevention has tips for preventing COVID-19 in the workplace.

Copyright 2020 HealthDay. All rights reserved.

Read More
medicine

IU School of Medicine partnering to increase greater access to psychiatric care in Northwest Indiana | Local News



STOCK_IU_Northwest

Indiana University Northwest




MERRILLVILLE — A new partnership is seeking to bring greater access to psychiatric care in Northwest Indiana.

The IU School of Medicine in collaboration with the Northwest Indiana GME Consortium is launching a new psychiatry resident program at IU Northwest to train psychiatrists in a four-year program.

The program, accredited by the Accreditation Council for Graduate Medical Education, will accept four residents each year.


IUN to offer degree exploration, admissions advice in virtual open house

It is the first psychiatry residency program in northern Indiana and the third in the IU School of Medicine, IU School of Medicine Northwest — Gary campus director Elizabeth Ryan said in a news release.

“The program contributes to a goal of recruiting medical students to the Northwest-Gary campus, upon medical school graduation transitioning to a Northwest Indiana-located residency program and retaining these physicians to serve in the Region,” Ryan said.

The United States Health Resources and Services Administration has designated Northwest Indiana as a high-needs geographic health professional shortage area, according to an IU School of Medicine news release.


250% spike in NWI COVID cases, rising positivity rates indicate worst is yet to come, professor says

The program’s partners say they hope the new cohort can help ease this gap.

Residents in the new program will be integrated into the network of Northwest Indiana GME Consortium partners, like Regional Health Systems in Merrillville.

Source Article

Read More
medicine

Stanford Medicine launches home COVID-19 testing study covering greater San Francisco

Stanford University and its school of medicine have launched plans to survey the population of greater San Francisco for COVID-19, in an effort to build an early warning system for future outbreaks.

Using a combination of self-collection testing kits and online reporting, the Community Alliance to Test Coronavirus at Home, or CATCH Study, aims to estimate the true prevalence of the disease among the 8.5 million people living in the Bay Area.

Ultimately, the study hopes to scale up a diagnostic infrastructure that can provide fast remote testing to a broad and representative sample of the population, including among the underserved and vulnerable across 12 counties. 

Featured Webinar

How to Streamline Your Clinical Research Organization’s Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

The program is currently seeking to enroll participants, who will report their exposures and symptoms daily through an online portal. 

RELATED: Stanford team deploys CRISPR gene editing to fight COVID-19

Home test kits—developed in collaboration with the Chan Zuckerberg Biohub, which is also helping to fund the study—will be delivered through the mail within 24 hours at no cost, and will contain a gentle nasal swab for self-collection. Samples will then be processed at Stanford’s laboratories.

“Our main objective is to learn where and how the virus is spreading—whether people are displaying symptoms or not—and which communities are most vulnerable,” said co-lead researcher Yvonne Maldonado, an associate professor of health research and policy at Stanford Medicine. 

“These insights will help our scientists and local public officials gain a deeper understanding of the distribution of COVID-19 throughout the greater San Francisco Bay Area so that they can stop its spread,” Maldonado said.

Source Article

Read More
medicine

Stanford Medicine Launches Study Of Greater San Francisco Bay Area Using Safe, Convenient COVID-19 Testing From Home

STANFORD, Calif., Oct. 20, 2020 /PRNewswire/ — The Stanford University School of Medicine today announced the launch of the Community Alliance to Test Coronavirus at Home (CATCH) Study, an effort that seeks to estimate the true population prevalence of COVID-19 across the 8.5 million population of the greater San Francisco Bay Area, and ultimately aid in the effort to reopen schools, workplaces and communities.

The CATCH Study is now seeking participants. A key aim of the CATCH Study is to scale a simple, safe, convenient, and population-scale early diagnostic system to help stop further undetected spread of COVID-19. CATCH utilizes online surveys and home delivered self-collection kits that are able to be rapidly deployed to carry out remote testing in a broad and representative sample of the population, including those underserved and vulnerable populations that might otherwise not be reached or tested. The study is enabled by the Vera Cloud Testing Platform including its novel Vera Home Test Kit, a gentle nasal swab self-collection kit that can be delivered directly to the homes of study participants by existing couriers and package delivery services.

There is no cost to CATCH Study participation, and all residents in the San Francisco Bay Area are welcome to enroll. Every participant joins online, reports their symptoms and exposures to COVID-19 daily, and may also be offered a home test kit at no cost upon reporting. If accepted, within 24 hours a home test kit will be delivered safely and conveniently by express courier to their home, where they can self-collect a sample, which is then delivered to the Stanford Health Care laboratory and tested for SARS-CoV-2 infection. All tested participants are informed of their results privately and securely online via their personal password-protected account within the CATCH website. The unique approach removes any requirement to leave home or shelter-in-place. 

The study is being led by Stanford Medicine researchers Yvonne Maldonado, MD, professor of pediatric infectious diseases and of health research and policy, Lorene Nelson, MD, associate professor of health research and policy, as well as Dr. Stephen Quake, professor of bioengineering and of applied physics and co-president of the Chan Zuckerberg Biohub.

“We encourage as many Bay Area residents as possible to sign-up for the CATCH Study to help increase our knowledge of a virus that has had significant impacts on our communities,” said Dr. Maldonado. “Our main objective is to learn where and how the virus is spreading — whether people are displaying symptoms or not — and which communities are most vulnerable. These insights will help our scientists and local public officials gain a deeper understanding of the distribution of COVID-19 throughout the greater San Francisco Bay Area so that they can stop its spread.”

With the effects of COVID-19 disproportionately affecting minority and vulnerable communities throughout the country, and specifically in the Bay Area, one of the key intentions of the study is to address inequities in testing by researching underserved populations. The testing kits will provide

Read More